Office of AIDS (OA) Management Memorandum
AIDS Drug Assistance Program (ADAP) Memorandum Number: 2020-01

DATE: January 14, 2020

TO: ADAP AND PREP-AP ENROLLMENT WORKERS

SUBJECT: RESTRICTION REVISION TO THE GARDASIL® 9 VACCINE ON THE ADAP AND PREP-AP FORMULARIES

**Effective January 14, 2020**, the age restriction listed for the human papillomavirus (HPV) 9-valent recombinant (Gardasil® 9) vaccine on the ADAP and PrEP-AP formularies have been revised. The revised restriction makes the vaccination available to clients up to the age of 45 and allows for coverage if a client turns 46 years of age after the vaccine series has begun to ensure completion of the treatment. This revision is based on the October 5, 2018, Federal Drug Administration approved expansion of the age indication for Gardasil® 9 through 45 years of age.

OA management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary and the PrEP-AP formulary have been updated to reflect the revision for Gardasil® 9. Access to the updated ADAP and PrEP-AP formularies are available at the following URLs: [https://cdph.magellanrx.com/member/documents](https://cdph.magellanrx.com/member/documents) and [https://cdphprep-ap.magellanrx.com/member/documents](https://cdphprep-ap.magellanrx.com/member/documents).

If you have any questions regarding the change made to the ADAP and PrEP-AP formularies, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Thank you,

Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health